FindTrial
Sign In

Role of Dapaglifozin in Lupus Nephritis

A Randomized Open Label Trial to evaluate effectiveness of Dapaglifozin in Lupus Nephritis - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/06/112959
Enrollment
84
Registered
2026-06-17
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M321- Systemic lupus erythematosus withorgan or system involvement

Interventions

Intervention1: Dapaglifozin: Patient will receive additional Dapaglifozin (10mg oral tablet once daily for 6 months) along with standard of care treatment with corticosteroid , non glucocorticoid immu

Sponsors

DR ROSHANI SRIDHAR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed with SLE with active Lupus Nephritis according to the ACR EULAR classification criteria 2019

Exclusion criteria

Exclusion criteria: Diabetes Mellitus eGFR less than 25mL/min APS nephropathy History of recurrent Urinary tract infection Pregnancy and lactation

Design outcomes

Primary

MeasureTime frame
Renal responseTimepoint: 6 months—

Secondary

MeasureTime frame
24 hour urine protein Disease activity parameters Urinary TGFbeta 1 by ELISA SGLT2 IHC in renal biopsy Adverse EventsTimepoint: 6 months—

Countries

India

Contacts

Public ContactDR PRADEEPTA SEKHAR PATRO

IMS & SUM Hospital Bhubaneswar

drpradeepta07@gmail.com9721799997

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026